Benzinga | Oct 21, 2020 12:17PM EDT

Craig-Hallum Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $195

Craig-Hallum analyst Matt Hewitt maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and lowers the price target from $215 to $195.